Pancreatic ductal adenocarcinoma and Lumican {#S1}
============================================

Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a high incidence of distant metastasis^[@R1]^ and is projected to be the second leading cause of cancer death by 2030^[@R2]^. The pathways that promote invasion and metastasis of PDAC are elusive. However, elucidating the mechanisms behind the metastatic efficiency of this deadly disease is important to develop a novel therapeutic approach. PDAC exhibits extensive desmoplastic stroma, which derives from activated pancreatic stellate cells. This activation results in proliferation, leading to the production of collagen, laminin, fibronectin^[@R3]^, and lumican^[@R4]^ within the extracellular matrix (ECM). Lumican, a member of a class II family of small leucine-rich proteoglycans, is highly upregulated in different cancer types, especially pancreas, breast, and cervical cancer^[@R5]--[@R8]^, and affects the proliferation, migration, and adhesion of cancer cells through a variety of mechanisms^[@R4],[@R9]--[@R13]^. Studies have demonstrated differential distribution of lumican between cancer cells and the reactive tumor stroma^[@R4],[@R13]--[@R16]^. In pancreatic cancer, lumican is specifically localized in alpha cells of islets, acinar cells, collagen fibrils, fibroblasts close to pancreatic cancer cells, and cancer cells^[@R5]^. Our previous report and others' confirm that pancreatic stellate cells are the major source of lumican production and secretion^[@R4],[@R6]^. Recently, it has been shown that heat shock protein 47 (HSP47) interacts with and promotes the secretion of lumican in the ECM^[@R17]^. Lumican was shown to influence cell function through various mechanisms in a tissue-specific manner in different cancers. In the tumor microenvironment (TME) of primary PDAC, the presence of lumican within the ECM has been positively and negatively correlated with tumor progression. It has previously been reported that the localization of lumican in the stromal tissue correlates with advanced-stage pancreatic cancer, retroperitoneal and duodenal invasion, and tends to correlate with shorter survival^[@R18]^. Degradation of lumican by matrix metalloproteinases MTI-MMP resulted in the abrogation of p21-mediated suppression of tum origenicity by lumican^[@R19]^. On the other hand, a recent study has demonstrated that glycosylated lumican possesses anti-tumor activity by directly interacting with the catalytic domain of M M P-14 and inhibiting its activity^[@R20]^. It was reported that lumican manifested anticancer activity in invasive breast cancer cells by modifying cell morphology, evoking EMT/MET reprogramming, and suppressing matrix metalloproteinases and epidermal growth factor receptors (EGFRs)^[@R21]^. Conversely, in the gastric cancer-associated fibroblasts, lumican activated the (β1 integrin-m ediated FAK signaling, thereby enhancing tumor grow th^[@R22]^. Moreover, secreted 70-kDa lumican by PDAC cells stimulated growth and inhibited invasion of human pancreatic cancer. It also activated ERK signaling, induced a 3 integrin expression, and decreased active matrix metalloproteinase-9^[@R23]^. On the contrary, lumican overexpression within the pancreatic cancer TME in vivo produced uniformly smaller tumors, correlated with reduced vascular density, enhanced Fas-mediated endothelial apoptosis, and reduced angiogenesis in TME^[@R24],[@R25]^. A key finding in our previous study was that the activated pancreatic stellate cells within the TME are the principle source of stromal lumican, and the presence of lumican within the stroma of a primary PDAC tumor is associated with decreased metastasis and prolonged survival in early-stage pancreatic cancer^[@R12],[@R13]^. Mechanistically, we demonstrated that the activated pancreatic stellate cells within PDAC secrete lumican under the negative control of TGF-β and enhance stellate cell adhesion and mobility in a collagen-rich environment^[@R4]^. We also demonstrated that extracellular lumican physically binds with EGFRs to trigger EGFR internalization, downregulation of EGFR, and its downstream signal. This resulted in apoptosis, glycolytic metabolism inhibition, and entry into a quiescent state^[@R12],[@R26]^. Mounting evidence reported in multiple studies on PDAC by our group^[@R4],[@R12],[@R13],[@R26]^ and several others using different cancer m odels^[@R15],[@R27]--[@R30]^ suggests that lumican is a key regulator of ECM and ECM-cell interactions within the TME. Overall, lumican is shown to have an anti-tumor role in a context-dependent manner, and the conflicting results regarding the precise role of lumican in tumor progression and regression depend on the specific correlation between lumican tissue-specific abundance, distribution, and stage of disease in PDAC.

Hypoxia Attenuates the Secretion of Lumican by Pancreatic Stellate Cells {#S2}
========================================================================

The PDAC TME is characterized by dense desmoplastic stroma and resultant hypoxia, which also drives angiogenesis, immune suppression, and numerous signaling events that promote cancer progression, metastasis, and poor patient survival.^[@R31]--[@R34]^ The influence of hypoxia on stromal composition and secreted extracellular protein such as lumican is not clearly understood. Therefore, in our recent publication^[@R35]^, our major focus was to investigate the extent to which hypoxia influences stromal expression and secretion of lumican in PDAC. We observed that hypoxia significantly reduced lumican expression and secretion from pancreatic stellate cells but not cancer cells. Our results revealed that hypoxia stimulates HIF-1α and AMP-regulated protein kinase (AMPK) activation, which leads to autophagy and subsequent reduction in cellular and secreted lumican ([Figure 1](#F1){ref-type="fig"}). We found that AMPK activation blocked the hypoxia-activated mTOR signaling pathway, which in turn inhibited lumican protein synthesis ([Figure 1](#F1){ref-type="fig"}). Therefore, the hypoxia-activated cell signaling event reduces the level of lumican production by stellate cells in the ECM of PDAC.

Desmoplastic fibrosis in PDAC tumors inhibits the delivery of nutrients and oxygen, which produces a TME that is characterized by hypoxia and metabolic stress. We expanded our study^[@R35]^ by applying a robust ex vivo organotypic live-tissue culture system to mimic tumor-stroma coevolution and provide a hypoxic environment that mimics the TME. The culture system consisted of precision-cut and uniform small tissue slices (200\^m) derived from patient-derived primary PDAC xenograft (PDX) tumors. Importantly, the tissue slices remained viable for at least 5 days. In our previous study, we have shown that microenvironment components, tumor architecture, and cell signaling pathways^[@R36]^ are well preserved in those tumor tissue slices. The slices were cultured in hypoxia (1% O2) for up to 48 hrs. and this unique ex vivo system allowed for the measurement of autophagic changes within the stroma and the reduction of stromal lumican that is exposed to hypoxic conditions. We went on to confirm the finding that hypoxia induces autophagy and attenuates lumican secretion by conducting in vitro studies using activated human stellate cells (HPSCs and HPaSTeC) cultured from human PDAC tumors.

Hypoxia-Induced Autophagy-Mediated Degradation of Lumican in Tumor Stroma {#S3}
=========================================================================

Cellular protein degradations are governed by 2 major pathways in the eukaryotic system: the ubiquitinproteosome system (UPS) and autophagy. The latter is primarily responsible for the degradation of aggregated proteins and cellular organelles^[@R37]^. The hypoxia and metabolic stress within the TME aggravated cellular autophagy. Previous autophagy-related studies focused only on cancer cells^[@R38],[@R39]^ but recent advancements in research on autophagy have led to a focus on the tumor stroma, preferably referred to as the "autophagic tumor stroma," which is an adaptation process where the autophagy of stromal cells provides fuel for cancer cells within the TME^[@R39]--[@R41]^. Next, to determine which pathway is involved in the lumican degradation process, stellate cells were treated with a UPS inhibitor and autophagy-lysosomal inhibitors in the normoxic and hypoxic environments. Our data indicated that hypoxia reduced stromal lumican via autophagy, not the UPS pathway. We went on to confirm this finding by knocking down proautophagic signaling gene Beclin 1 (Atg6)^[@R42]^ by using RNA interference. Silencing of Beclin 1 set back the hypoxia-induced decrease in lumican that is noticed in stellate cells. We also confirmed the cellular colocalization of the lumican and lysosomal marker LAMP in hypoxic stellate cells. This indicated that lumican is predominantly transported to the lysosome when stellate cells are hypoxic. It is well accepted that hypoxia initiates tumor cell autophagy in different cancers^[@R43]--[@R45]^. In our recent study^[@R35]^, we sought to determine whether hypoxia promotes autophagy within pancreatic stellate cells, and our investigation resulted in increasing expressions of the canonical autophagic marker LC3 in both stellate cells and PDX slices that were cultured selectively in hypoxic conditions. Our observations suggested that hypoxia induces autophagy, which results in the degradation of lumican within PDAC stellate cells.

Activated AMPK Negatively Regulates Hypoxia-Induced Stromal Lumican Synthesis {#S4}
=============================================================================

HIF-1α and the proautophagic module AMPK have been known to influence hypoxia-induced autophagy^[@R46]--[@R48]^. Inquisitively, we have investigated their role in mediating hypoxia-induced autophagy in pancreatic stromal cells. We evaluated the colocalizations of lumican with HIF-1α and phosphorylated AMPK at the interface between cancer cells and stromal cells in patient tumor tissues. Hypoxia stimulated AMPK activation and the increased expressions of HIF-1α and LC3 in vitro and ex vivo. Treatments consisting of pharmacological AMPK inhibitors and siRNA knockdown of HIF-1 α both inhibited hypoxia-induced reduction of lumican expressions. Intriguingly, to define the role of HIF-1α, we transfected the stellate cells with w ild type and mutant HIF-1 α construct. We noticed that the native HIF-1α, not the mutant, is required for lumican degradation in stromal cells. Therefore, hypoxia-related HIF-1α and AMPK activation mediated the induction of autophagy in the stroma, resulting in lumican degradation. Mechanistically, we found that hypoxia does not influence lumican protein synthesis transcriptionally. We next targeted PI3K/Akt/mTOR pathways and their downstream signaling in stromal cells and in PDX slices in hypoxia to examine the involvement of translational machinery related to lumican protein synthesis. Interestingly, Akt phosphorylation was significantly increased, whereas its remaining antiautophagic node signals, mTOR, P70S6K, and 4-EBP-1 ([Figure 1](#F1){ref-type="fig"}), were decreased during exposure to hypoxia. This finding is concomitant with the hypoxia-enhanced AM PK activation. Previous literature has suggested that Akt-mediated mTOR signaling can be blocked by activated pro-autophagic signaling molecule AMPK, which phosphorylates TSC2^[@R49],[@R50]^. Interestingly, treatment of stellate cells with the AMPK inhibitor reversed the hypoxia-related reduction in the mTOR pathway and its downstream signaling ([Figure 1](#F1){ref-type="fig"}). Moreover, it also enhanced the lumican expression transcriptionally, which indicated that hypoxia-induced mTOR activation was blocked by activated AMPK. Therefore, molecular mechanistic studies by our group demonstrated that activated AM PK in hypoxic stellate cells negatively impacts lumican protein synthesis.

Downregulation of Stromal Lumican is not Influenced by Increased Lactate Production {#S5}
===================================================================================

Nearly a century ago, Warburg and his colleague made the seminal observation that the common feature of cancer cell metabolism is increased glucose uptake and the fermentation of glucose into lactate to promote growth, survival, proliferation, and long-term maintenance^[@R51]^. The lactate can be transferred to other cells through specialized transporters, which provides another fuel source for oxidative mitochondrial metabolism^[@R52],[@R53]^. Recently, stromal cells have been recognized as a lactate source for use by cancer cells^[@R54]^. Therefore, in this context, we examined whether stromal lactate, triggered by hypoxia, influenced the observed reduction of lumican in TME. We found that the presence or absence of lactate did not influence lumican expression, although hypoxia dramatically enhanced the lactate dehydrogenase A (LDHA) expression and secretion of lactate in stromal cells. Our future study will assess the expression of a lactate transporter, monocarboxylate transporter 1 (MCT1), and the activation of AMPK and HIF-1α in PDAC stromal cells to gain a better insight into lactate shuttling from PDAC to its stromal cells.

Conclusions {#S6}
===========

This review summarizes our recent publication^[@R35]^ addressing the factors within the TME that influence lumican production in stromal cells. We consistently found that 1) hypoxia-induced autophagy in PDAC stellate cells; 2) subsequent lumican degradation occurred exclusively in stromal cells, leaving the cancer cells, indicating that stellate cells are more sensitive to hypoxia with respect to lumican levels; and 3) stromal autophagy decreased stromal lumican secretion, which was linked to tumor growth^[@R12],[@R13]^. In conclusion, these recent findings by our group provide important new insights to build and deepen our understanding of the molecular interactions between stromal lumican and the TME and provide a rationale to design credible antitumor approaches against pancreatic cancer.
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